ams-OSRAM AG (SWX:AMS)
Switzerland · Delayed Price · Currency is CHF 10.68
+0.27 (2.59%)
Aug 8, 2025, 5:31 PM CET
CTI BioPharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 3,358 | 3,428 | 3,590 | 4,819 | 5,038 | 3,504 | Upgrade | |
Revenue Growth (YoY) | -3.42% | -4.51% | -25.50% | -4.35% | 43.78% | 85.89% | Upgrade |
Cost of Revenue | 2,402 | 2,448 | 2,568 | 3,351 | 3,327 | 2,469 | Upgrade |
Gross Profit | 956 | 980 | 1,022 | 1,468 | 1,711 | 1,035 | Upgrade |
Selling, General & Admin | 431 | 422 | 501 | 608 | 697 | 527 | Upgrade |
Research & Development | 372 | 419 | 480 | 630 | 692 | 423 | Upgrade |
Other Operating Expenses | -44 | -10 | -14 | -11 | -8 | -34 | Upgrade |
Operating Expenses | 759 | 831 | 967 | 1,227 | 1,381 | 916 | Upgrade |
Operating Income | 197 | 149 | 55 | 241 | 330 | 119 | Upgrade |
Interest Expense | -342 | -272 | -180 | -198 | -179 | -227 | Upgrade |
Interest & Investment Income | 116 | 40 | 22 | 14 | 5 | 5 | Upgrade |
Earnings From Equity Investments | -6 | -7 | -24 | -4 | -33 | -5 | Upgrade |
Currency Exchange Gain (Loss) | -12 | -12 | -38 | -13 | -70 | -6 | Upgrade |
Other Non Operating Income (Expenses) | 40 | 41 | 27 | -18 | 27 | 9 | Upgrade |
EBT Excluding Unusual Items | -7 | -61 | -138 | 22 | 80 | -105 | Upgrade |
Merger & Restructuring Charges | -136 | -123 | -182 | -209 | -262 | - | Upgrade |
Impairment of Goodwill | - | - | -1,313 | -277 | -2 | -10 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | 3 | 97 | - | Upgrade |
Gain (Loss) on Sale of Assets | 8 | 8 | 46 | 152 | 66 | 9 | Upgrade |
Asset Writedown | - | - | -13 | -52 | - | - | Upgrade |
Other Unusual Items | 56 | -576 | - | - | 20 | 1 | Upgrade |
Pretax Income | -79 | -752 | -1,600 | -361 | -1 | -81 | Upgrade |
Income Tax Expense | 36 | 33 | 12 | 82 | 31 | 10 | Upgrade |
Earnings From Continuing Operations | -115 | -785 | -1,612 | -443 | -32 | -91 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | 3 | Upgrade |
Net Income to Company | -115 | -785 | -1,612 | -443 | -32 | -88 | Upgrade |
Minority Interest in Earnings | -1 | -1 | -1 | -1 | 1 | 75 | Upgrade |
Net Income | -116 | -786 | -1,613 | -444 | -31 | -13 | Upgrade |
Net Income to Common | -116 | -786 | -1,613 | -444 | -31 | -13 | Upgrade |
Shares Outstanding (Basic) | 99 | 99 | 31 | 26 | 26 | 22 | Upgrade |
Shares Outstanding (Diluted) | 99 | 99 | 31 | 26 | 26 | 22 | Upgrade |
Shares Change (YoY) | 47.41% | 218.77% | 18.72% | 0.04% | 21.36% | 161.44% | Upgrade |
EPS (Basic) | -1.17 | -7.95 | -52.00 | -16.99 | -1.19 | -0.60 | Upgrade |
EPS (Diluted) | -1.17 | -7.95 | -52.00 | -17.00 | -1.20 | -0.60 | Upgrade |
Free Cash Flow | 61 | -67 | -556 | 62 | 482 | 530 | Upgrade |
Free Cash Flow Per Share | 0.61 | -0.68 | -17.93 | 2.37 | 18.46 | 24.63 | Upgrade |
Gross Margin | 28.47% | 28.59% | 28.47% | 30.46% | 33.96% | 29.54% | Upgrade |
Operating Margin | 5.87% | 4.35% | 1.53% | 5.00% | 6.55% | 3.40% | Upgrade |
Profit Margin | -3.45% | -22.93% | -44.93% | -9.21% | -0.61% | -0.37% | Upgrade |
Free Cash Flow Margin | 1.82% | -1.95% | -15.49% | 1.29% | 9.57% | 15.13% | Upgrade |
EBITDA | -6 | 462 | 429 | 782 | 990 | 624 | Upgrade |
EBITDA Margin | -0.18% | 13.48% | 11.95% | 16.23% | 19.65% | 17.81% | Upgrade |
D&A For EBITDA | -203 | 313 | 374 | 541 | 660 | 505 | Upgrade |
EBIT | 197 | 149 | 55 | 241 | 330 | 119 | Upgrade |
EBIT Margin | 5.87% | 4.35% | 1.53% | 5.00% | 6.55% | 3.40% | Upgrade |
Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.